Pharma Foods International Co., Ltd (PMDSF) fair value: what the stock is really worth
As of Sep 18, 2026: fair value of Pharma Foods International Co., Ltd $11.14, price $6.40, upside +74.1%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Pharma Foods International Co., Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
23‑month range $5.39 – $6.40 · fair‑value band $8.35 – $15.02 · the $6.40 price screens below the $11.14 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Pharma Foods International Co. in your weekly email
Every Wednesday you see whether Pharma Foods International Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pharma Foods International Co., Ltd. engages in the development and sale of functional food ingredients in Japan. It also focuses on biomedical drug discovery of antibody and peptide drugs targeting diseases, including autoimmune, cancer, and inflammatory. The company was founded in 1997 and is headquartered in Kyoto, Japan.
Stock analysis
Pharma Foods International Co., Ltd (PMDSF) currently trades at $6.40, while our model-based Fair Value estimate is $11.14, implying the stock looks roughly 42.5% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $11.20 per share, and 16 of the 21 models we run sit above the $6.40 price.
Bear case: the Asset-Based group reads lowest at $1.55, and 5 of the 21 models stay below the price. Evidence for this calculation is medium.
Scenario range: $8.35 (bear) to $15.02 (bull), the price of $6.40 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Pharma Foods International Co., Ltd reported revenue of ¥62.1B in FY2024 versus ¥60.2B in FY2022, a compound +1.6%/yr. Reported net income was ¥3.2B in FY2024.
Key figures
Market cap $180M · P/E ratio 8.8 · P/S ratio 0.45 · EPS (TTM) $0.7300 · Net margin 5.2% · Return on equity 4.2% · Return on assets (EBIT) 9.4% · Operating margin 5.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 3% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 74%, PMDSF screens cheaper than that median.
Fair Value models
Bear $8.35Fair Value $11.14Bull $15.02
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.33/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−7.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about −9.7% a year for the price.
Compare Pharma Foods International Co., Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside+74% · Top 25%
Profitability
Return on equity (TTM)4% · Below median
Return on assets2% · Below median
Net margin (TTM)1% · Below median
Operating margin (TTM)6% · Below median
Growth and dividend
Revenue growth−5% · Below median
Balance sheet
Debt / equity0.11× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Pharma Foods International Co., Ltd Fair Value". https://www.fairvalue-calculator.com/stock/PMDSF
Frequently asked questions
Is Pharma Foods International Co., Ltd (PMDSF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $11.14 versus the last price from Sep 18, 2026 of $6.40, about +74% upside (undervalued).
What is the fair value of PMDSF?
Our model-based fair value for Pharma Foods International Co., Ltd is $11.14 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 18, 2026): $6.40.
What is the quality score of PMDSF?
Pharma Foods International Co., Ltd has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharma Foods International Co., Ltd (PMDSF)?
Our model-based price target is the fair value of $11.14 (as of Sep 24, 2026) from 21 valuation models. Cautious scenario $8.35, optimistic scenario $15.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharma Foods International Co., Ltd stock forecast for 2026?
Our models put fair value at $11.14, about +74% upside versus the last price from Sep 18, 2026 of $6.40 (undervalued). Cautious scenario $8.35, optimistic scenario $15.02. The calculation is refreshed regularly with new filings.
What is the revenue of Pharma Foods International Co., Ltd (PMDSF)?
Pharma Foods International Co., Ltd reported trailing-twelve-month revenue of about ¥67.0B (latest available figure, as of Sep 24, 2026).
What growth is priced into Pharma Foods International Co., Ltd (PMDSF)?
For today's price to be fair in a discounted-cash-flow model, Pharma Foods International Co., Ltd would have to grow free cash flow by -7.8 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 2 years revenue grew +1.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of PMDSF use?
Our models discount Pharma Foods International Co., Ltd at 11.2 %: a base by market capitalisation (micro), damped by beta 0.33, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pharma Foods International Co., Ltd that is -7.8 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Pharma Foods International Co., Ltd (PMDSF) delivered so far?
Over the past 2 years revenue at Pharma Foods International Co., Ltd grew +1.6 % a year. The price currently implies -7.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Pharma Foods International Co., Ltd (PMDSF) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Pharma Foods International Co., Ltd (-7.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Pharma Foods International Co., Ltd (PMDSF)?
The free-cash-flow yield on the price is 15.89 %: that much free cash flow Pharma Foods International Co., Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Pharma Foods International Co., Ltd (PMDSF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharma Foods International Co., Ltd it is $11.14 per share (as of Sep 24, 2026), against a price of $6.40. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is Pharma Foods International Co., Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, PMDSF trades below its calculated fair value: price $6.40, fair value $11.14, a gap of about +74% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PMDSF?
No. The price is what the market pays today ($6.40); the fair value is what the company's own numbers justify ($11.14). For Pharma Foods International Co., Ltd the two are $4.74 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharma Foods International Co., Ltd worth?
The market values Pharma Foods International Co., Ltd at about $180M (market capitalisation, as of Sep 24, 2026). Per share that is $6.40; our models calculate a fair value of $11.14 per share.
What do the bullish and bearish scenarios say about PMDSF?
Our models span a range for Pharma Foods International Co., Ltd: cautious scenario $8.35, base $11.14, optimistic $15.02 per share (as of Sep 24, 2026, price $6.40). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PMDSF?
Pharma Foods International Co., Ltd trades at a price-to-earnings ratio of 8.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $11.14 is built from several models across several years.
How solid is the balance sheet of Pharma Foods International Co., Ltd (PMDSF)?
Balance-sheet figures for Pharma Foods International Co., Ltd (as of Sep 24, 2026): return on equity 4.2%, debt of 0.11 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is PMDSF from its 52-week high?
Pharma Foods International Co., Ltd trades at $6.40, at its 52-week high of $6.40 and 3% above the low of $6.24 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $11.14 is for.
Which stocks are comparable to Pharma Foods International Co., Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharma Foods International Co., Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price $6.40, calculated fair value $11.14 (+74%), Quality Score 60/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PMDSF calculated?
We run Pharma Foods International Co., Ltd through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $11.14, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Pharma Foods International Co., Ltd currently trades 74 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharma Foods International Co., Ltd (PMDSF)?
The latest price we hold is from Sep 18, 2026 and stands at $6.40. Our model-based fair value is $11.14, about +74% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharma Foods International Co., Ltd right now?
The price is below even our cautious bear case ($8.35). The market is more pessimistic than our downside scenario. Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Pharma Foods International Co., Ltd
How large is the market capitalisation of Pharma Foods International Co., Ltd (PMDSF)?
The market capitalisation of Pharma Foods International Co., Ltd is $180M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharma Foods International Co., Ltd (PMDSF)?
The price-to-sales ratio of Pharma Foods International Co., Ltd is 0.45 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pharma Foods International Co., Ltd (PMDSF)?
Earnings per share at Pharma Foods International Co., Ltd are $0.7300 (price ÷ EPS = P/E 8.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pharma Foods International Co., Ltd (PMDSF)?
The net margin of Pharma Foods International Co., Ltd is 5.2% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharma Foods International Co., Ltd (PMDSF)?
The return on equity (ROE) of Pharma Foods International Co., Ltd is 4.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharma Foods International Co., Ltd (PMDSF)?
On an EBIT basis the return on assets of Pharma Foods International Co., Ltd is 9.4% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharma Foods International Co., Ltd (PMDSF)?
The operating margin of Pharma Foods International Co., Ltd is 5.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharma Foods International Co., Ltd (PMDSF)?
Revenue at Pharma Foods International Co., Ltd is growing −5.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Pharma Foods International Co., Ltd (PMDSF) carry?
The net debt of Pharma Foods International Co., Ltd is ¥1.2B (fiscal year 2024, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Pharma Foods International Co., Ltd in the live analysis
One click puts Pharma Foods International Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026